- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 26, Issue 17, 2019
Current Medicinal Chemistry - Volume 26, Issue 17, 2019
Volume 26, Issue 17, 2019
-
-
Histone Deacetylase Inhibitors in Tumor Immunotherapy
Authors: Li-Ming Zhao and Jie-Huan ZhangBackground: With an increasing understanding of the antitumor immune response, considerable progress has been made in the field of tumor immunotherapy in the last decade. Inhibition of histone deacetylases represents a new strategy in tumor therapy and histone deacetylase inhibitors have been recently developed and validated as potential antitumor drugs. In addition to the direct antitumor effects, histone deacetylas Read More
-
-
-
Immune Checkpoint Inhibitors: Basics and Challenges
Authors: Bin Li, Ho L. Chan and Pingping ChenCancer is one of the most deadly diseases in the modern world. The last decade has witnessed dramatic advances in cancer treatment through immunotherapy. One extremely promising means to achieve anti-cancer immunity is to block the immune checkpoint pathways – mechanisms adopted by cancer cells to disguise themselves as regular components of the human body. Many review articles have described a variet Read More
-
-
-
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Authors: Weiqiang Zhou, Shanchun Guo, Mingli Liu, Matthew E. Burow and Guangdi WangChemokines, which have chemotactic abilities, are comprised of a family of small cytokines with 8-10 kilodaltons. Chemokines work in immune cells by trafficking and regulating cell proliferation, migration, activation, differentiation, and homing. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also known as CXCL12), which has been found to be expressed in more than 23 different types of canc Read More
-
-
-
Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Authors: Manee Patanapongpibul and Qiao-Hong ChenVarious exciting immunotherapies aiming to address immune deficiency induced by tumor and treatment hold promise in improving the quality of life and survival rate of cancer patients. It is thus becoming an important and rewarding arena to develop some appropriate immune modulators for cancer prevention and/or treatment. Exploitation of natural products-based immune modulators is of particular imperative because t Read More
-
-
-
Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Authors: Lu Hao, Tongtong Li, Lung-Ji Chang and Xiaochuan ChenBackground: Adoptive infusion of chimeric antigen receptor transduced T- cells (CAR-T) is a powerful tool of immunotherapy for hematological malignancies, as evidenced by recently published and unpublished clinical results. Objective: In this report, we performed a meta-analysis to evaluate the efficacy and side effects of CAR-T on refractory and/or relapsed B-cell malignancies, including leukemia and lymphoma. Me Read More
-
-
-
Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Authors: Cherie Stayner, Darby G. Brooke, Michael Bates and Michael R. EcclesBackground: Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening genetic disease in humans, affecting approximately 1 in 500 people. ADPKD is characterized by cyst growth in the kidney leading to progressive parenchymal damage and is the underlying pathology in approximately 10% of patients requiring hemodialysis or transplantation for end-stage kidney disease. The two Read More
-
-
-
Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies
Authors: Cedric R. Uytingco, Warren W. Green and Jeffrey R. MartensBackground: Ciliopathies are a class of inherited pleiotropic genetic disorders in which alterations in cilia assembly, maintenance, and/or function exhibit penetrance in the multiple organ systems. Olfactory dysfunction is one such clinical manifestation that has been shown in both patients and model organisms. Existing therapies for ciliopathies are limited to the treatment or management of symptoms. The last decade has see Read More
-
-
-
Ocular Ciliopathies: Genetic and Mechanistic Insights into Developing Therapies
Authors: Mahesh Shivanna, Manisha Anand, Subhabrata Chakrabarti and Hemant KhannaDeveloping suitable medicines for genetic diseases requires a detailed understanding of not only the pathways that cause the disease, but also the identification of the genetic components involved in disease manifestation. This article focuses on the complexities associated with ocular ciliopathies – a class of debilitating disorders of the eye caused by ciliary dysfunction. Ciliated cell types have been identified in both the Read More
-
-
-
Current Trends and Future Directions of Fluoroquinolones
Fluoroquinolones represent an interesting synthetic class of antimicrobial agents with broad spectrum and potent activity. Since the discovery of nalidixic acid, the prototype of quinolones, several structural modifications to the quinolone nucleus have been carried out for improvement of potency, spectrum of activity, and to understand their structure activity relationship (SAR). The C-7 substituent was reported to have a Read More
-
-
-
Use of Antibiotic Loaded Biomaterials for the Management of Bone Prosthesis Infections: Rationale and Limits
Authors: M. Tschon, M. Sartori, D. Contartese, G. Giavaresi, N. N. Aldini and M. FiniBackground: Periprosthetic joint infection still represents a challenging issue for the orthopedic community. In the United States approximately a million joint arthroplasties are performed each year, with infection rates ranging from 1 to 2%: revisions has significant implications on health care costs and appropriate resource management. The use of locally applied antibiotics as a prophylaxis measure or as a component of the t Read More
-
-
-
Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa
More LessFactor Xa (FXa) plays a key role in haemostasis, it is a central part of the blood coagulation cascade which catalyzes the production of thrombin and leads to clot formation and wound closure. Therefore, FXa is an attractive target for the development of new anticoagulant agents. In this review, we will first describe the molecular features of this fundamental protein in order to understand its mechanism of action, an essential bac Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
